Adaptive Biotechnologies (STU:1HM) 6-Month Share Buyback Ratio : -0.21% (As of Dec. 2024 )

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Adaptive Biotechnologies's current 6-Month Share Buyback Ratio was -0.21%.

Competitive Comparison of Adaptive Biotechnologies's 6-Month Share Buyback Ratio

For the Biotechnology subindustry, Adaptive Biotechnologies's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies's 6-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's 6-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Adaptive Biotechnologies 6-Month Share Buyback Ratio Calculation

Adaptive Biotechnologies's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

6-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Jun. 2024 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Jun. 2024 )
	=	(147.462	-	147.774)	/	147.462
	=	-0.21%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies (STU:1HM) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Adaptive Biotechnologies 6-Month Share Buyback Ratio Related Terms

Adaptive Biotechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (STU:1HM) » Definitions » 6-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

ADPT:USA 1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Adaptive Biotechnologies Headlines

No Headlines